Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  MDM2 antagonist RO5045337
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-7 of 7 for your search:
Start Over
A Study of RO5045337 [RG7112] in Patients With Advanced Solid Tumors
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: NO21280, NCT00559533
A Study of RO5045337 [RG7112] in Patients With Hematologic Neoplasms.
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: NO21279, NCT00623870
A Study of RO5045337 in Patients With Liposarcomas Prior to Debulking Surgery
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: NP22890, 2009-015522-10, NCT01143740
A Study of RO5045337 in Patients With Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: NP25299, NCT01164033
A Study of RO5045337 in Combination With Doxorubicin in Patients With Soft Tissue Sarcoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: NP28021, 2011-006279-21, NCT01605526
A Study of RO5045337 in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: NP28023, 2011-006252-36, NCT01635296
An Extension Study of RO5045337 in Patients Participating in Previous Cancer Studies
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: NP28366, 2012-001303-20, NCT01677780
Start Over